These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1000 related articles for article (PubMed ID: 25029122)
1. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Epstein JI; Egevad L; Humphrey PA; Montironi R; Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Herawi M; Epstein JI Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076 [TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Kunju LP; Mehra R; Snyder M; Shah RB Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367 [TBL] [Abstract][Full Text] [Related]
5. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Amin MB; Trpkov K; Lopez-Beltran A; Grignon D; Am J Surg Pathol; 2014 Aug; 38(8):e20-34. PubMed ID: 25029121 [TBL] [Abstract][Full Text] [Related]
6. Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma. Boran C; Kandirali E; Yilmaz F; Serin E; Akyol M Urol Oncol; 2011; 29(6):614-23. PubMed ID: 20189848 [TBL] [Abstract][Full Text] [Related]
7. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall. Gordetsky J; Epstein JI Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758 [TBL] [Abstract][Full Text] [Related]
8. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells. Ali TZ; Epstein JI Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120 [TBL] [Abstract][Full Text] [Related]
9. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Sheridan T; Herawi M; Epstein JI; Illei PB Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190 [TBL] [Abstract][Full Text] [Related]
10. [Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer]. Yu T; Zhu SX; Zheng S; Chen SP Zhonghua Nan Ke Xue; 2007 Mar; 13(3):222-5. PubMed ID: 17393784 [TBL] [Abstract][Full Text] [Related]
11. Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations. Shah RB; Kunju LP; Shen R; LeBlanc M; Zhou M; Rubin MA Am J Clin Pathol; 2004 Oct; 122(4):517-23. PubMed ID: 15487448 [TBL] [Abstract][Full Text] [Related]
12. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. Zhou M; Shah R; Shen R; Rubin MA Am J Surg Pathol; 2003 Mar; 27(3):365-71. PubMed ID: 12604893 [TBL] [Abstract][Full Text] [Related]
13. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases. Zhao J; Epstein JI Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862 [TBL] [Abstract][Full Text] [Related]
15. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System. Pierconti F; Martini M; Cenci T; Petrone GL; Ricci R; Sacco E; Bassi PF; Larocca LM Prostate; 2017 May; 77(6):597-603. PubMed ID: 28144985 [TBL] [Abstract][Full Text] [Related]
16. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer". He H; Magi-Galluzzi C; Li J; Carver P; Falzarano S; Smith K; Rubin MA; Zhou M Am J Surg Pathol; 2011 Apr; 35(4):608-14. PubMed ID: 21383613 [TBL] [Abstract][Full Text] [Related]
17. Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies. Shah RB; Magi-Galluzzi C; Han B; Zhou M Am J Surg Pathol; 2010 Apr; 34(4):470-7. PubMed ID: 20182345 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry in diagnostic surgical pathology of the prostate. Hameed O; Humphrey PA Semin Diagn Pathol; 2005 Feb; 22(1):88-104. PubMed ID: 16512601 [TBL] [Abstract][Full Text] [Related]
19. Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study. Wang W; Sun X; Epstein JI Am J Surg Pathol; 2008 Jun; 32(6):851-7. PubMed ID: 18408595 [TBL] [Abstract][Full Text] [Related]
20. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]